CJC-1295 DAC

CJC-1295 DAC – Long-Acting Growth Hormone Releasing Hormone (GHRH) Research Peptide

For Professional Research Use Only

CJC-1295 DAC (Drug Affinity Complex) is a long-acting synthetic analogue of growth hormone–releasing hormone (GHRH), developed for advanced research into growth hormone (GH) signalling, endocrine regulation, and anabolic pathway activation.

By incorporating a Drug Affinity Complex, CJC-1295 DAC is engineered to extend biological half-life, allowing sustained stimulation of endogenous GH release in controlled research environments.

What Is CJC-1295 DAC?

CJC-1295 DAC is a modified GHRH peptide designed to resist enzymatic degradation and bind to circulating proteins, significantly prolonging its activity compared to native GHRH and non-DAC variants.

The inclusion of the Drug Affinity Complex enables:

• Extended circulation time

• Sustained receptor engagement

• Reduced dosing frequency in research protocols

• Stable and prolonged GH signalling

These properties make CJC-1295 DAC especially useful for long-term endocrine and growth-related research models.

Key Research Applications

CJC-1295 DAC is commonly studied in laboratory research focused on:

• Growth hormone secretion and regulation

• Endocrine signalling dynamics

• Muscle growth and tissue recovery models

• Metabolic signalling and nutrient partitioning research

• Anti-catabolic pathway investigation

• Long-term GH pathway activation studies

Its extended activity profile allows researchers to examine continuous GH modulation without reliance on pulsatile stimulation.

Mechanism of Action

CJC-1295 DAC binds to GHRH receptors in the pituitary, stimulating the release of endogenous growth hormone. The Drug Affinity Complex enables prolonged receptor interaction by anchoring the peptide to serum proteins, preventing rapid breakdown.

This results in:

• Sustained GH release

• Enhanced downstream anabolic signalling

• Prolonged activation of GH-dependent metabolic pathways

The long-acting nature of CJC-1295 DAC differentiates it from short-acting GHRH analogues used in pulse-based research.

Scientific & Research Insight

Preclinical and laboratory research suggests that CJC-1295 DAC:

• Maintains elevated GH levels over extended periods

• Supports anabolic and regenerative signalling pathways

• Enhances research efficiency in long-duration studies

• Enables consistent GH exposure in controlled models

These characteristics have established CJC-1295 DAC as a foundational compound in long-term growth hormone research.

Product Specifications

• Compound: CJC-1295 DAC

• Quantity: 5 mg

• Form: Research-grade peptide

Supplied in a precision-measured format to support reproducible laboratory research.

Product Quality & Purity

• Third-party lab tested

• ≥99% purity

• Batch-verified for consistency

• Manufactured under strict quality control standards

• Designed for dependable research outcomes

Each batch is produced to ensure reliability across research applications.

Important Research Disclaimer

This product is strictly for laboratory and research use only.

• Not approved for human or veterinary consumption

• Not a dietary supplement or pharmaceutical product

• Intended solely for controlled research environments

• Purchasers must be 18+ and comply with all applicable regulations

Storage Guidelines

• Store lyophilised product in a freezer

• Refrigerate reconstituted solutions at 2–8°C

• Maintain sterile handling conditions to preserve research integrity

Why Choose Us?

• Premium-grade research peptides

• Transparent purity and batch verification

• Fast and discreet shipping

• Reliable supply for long-term research projects

Summary

CJC-1295 DAC is a long-acting GHRH research peptide engineered for sustained growth hormone stimulation in laboratory settings. Its extended half-life and stable signalling profile make it an essential tool for advanced endocrine, metabolic, and anabolic research requiring prolonged GH pathway activation.